{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:37Z","timestamp":1792700017038,"version":"4.5.0"},"reference-count":34,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Psoriatic arthritis (PsA) requires long\u2010term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long\u2010term Assessment of Clinical Efficacy (PALACE) 1, 2, and 3 data describes 3\u2010year apremilast safety and tolerability in PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with active PsA were randomized (1:1:1) to placebo, apremilast 30 mg twice daily, or apremilast 20 mg twice daily. Placebo patients were re\u2010randomized to apremilast 30 mg twice daily or 20 mg twice daily at week 16 (early escape) or 24. Double\u2010blind treatment continued to week 52; patients could continue apremilast during an open\u2010label, long\u2010term treatment phase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 1493 patients received at least one dose of study medication and were included in the safety population (placebo: n = 495; apremilast 30 mg: n = 497; apremilast 20 mg: n = 501). Among patients receiving apremilast, 53.2% (767\/1441) completed 3 years of treatment. Greater rates of adverse events (AEs) were reported with apremilast (61.1%; exposure\u2010adjusted incidence rate [EAIR]\/100 patient\u2010years, 265.1) versus placebo (47.5%; EAIR\/100 patient\u2010years, 200.7) in the placebo\u2010controlled period. During weeks 0 to \u226452, the most common AEs occurring in apremilast\u2010exposed patients were diarrhea (13.9%; EAIR\/100 patient\u2010years, 18.6), nausea (12.3%; EAIR\/100 patient\u2010years, 16.0), headache (9.4%; EAIR\/100 patient\u2010years, 12.1), upper respiratory tract infection (9.1%; EAIR\/100 patient\u2010years, 11.5), and nasopharyngitis (6.2%; EAIR\/100 patient\u2010years, 7.7). Most AEs were mild\/moderate with apremilast exposure \u2264156 weeks. Rates of depression remained low (EAIR\/100 patient\u2010years, 1.8). Major adverse cardiac events (EAIR\/100 patient\u2010years, 0.5), malignancies (EAIR\/100 patient\u2010years, 0.9), and serious opportunistic infections (EAIR\/100 patient\u2010years, 0.0) were infrequent over the 3\u2010year exposure period. Discontinuation rates due to AEs were low (&lt;7.5%) across all apremilast\u2010exposure periods. Incidences of clinically meaningful abnormalities in postbaseline laboratory values was low; most values returned to baseline levels with continued treatment and without intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Apremilast demonstrated a favorable safety profile and was well tolerated up to 156 weeks.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11156","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T03:04:43Z","timestamp":1595646283000},"page":"459-470","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Long\u2010Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials"],"prefix":"10.1002","volume":"2","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[{"name":"Swedish Medical Center\/Providence St. Joseph Health, Seattle, Washington and University of Washington School of Medicine Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[{"name":"Krembil Research Institute Toronto Western Hospital Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Gomez\u2010Reino","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Dominguez, Hospital Cl\u00ednico Universitario Santiago Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[{"name":"Monash University, Cabrini Health Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lespessailles","sequence":"additional","affiliation":[{"name":"Regional Hospital University of Orl\u00e9ans Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg, Erlangen, Germany und Universit\u00e4tsklinikum Erlangen Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Paris","sequence":"additional","affiliation":[{"name":"Amgen Inc Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Delev","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichen","family":"Teng","sequence":"additional","affiliation":[{"name":"Amgen Inc Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wollenhaupt","sequence":"additional","affiliation":[{"name":"J\u00fcrgen Wollenhaupt: Sch\u00f6n Klinik Hamburg Eilbek Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0169-x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13150"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2670"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2546-x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.02.001"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2014.897333"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000152"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207980"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3374-y"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130797"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23185"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3396-5"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.05.014"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140647"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"e_1_2_7_22_1","unstructured":"New South Wales Government Health.List of countries with a tuberculosis incidence of 40 cases per 100 000 persons or greater. October2019. URL:https:\/\/www.health.nsw.gov.au\/Infectious\/tuberculosis\/Pages\/high\u2010incidence\u2010countries.aspx."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2013-0228OC"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417748886"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.01.001"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2010.03.004"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2632-z"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/157201"},{"key":"e_1_2_7_30_1","unstructured":"Daliresp [package insert].Wilmington (DE):AstraZeneca Pharmaceuticals;2020."},{"key":"e_1_2_7_31_1","unstructured":"National Institute of Mental Health.Thoughts of suicide and made suicide plans.2019. URL:http:\/\/www.nimh.nih.gov\/health\/statistics\/suicide\/thoughts\u2010of\u2010suicide\u2010and\u2010made\u2010suicide\u2010plans.shtml."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000588"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38385"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/annrheumdis-2019-eular.1476","article-title":"AB0773. Psoriatic arthritis impact of disease questionnaire scores are correlated with disease activity, as measured by CDAPSA, in patients with psoriatic arthritis [abstract]","volume":"78","author":"Orbai AM","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_35_1","unstructured":"KleynCE.Apremilast real\u2010world treatment outcomes in psoriasis patients with comorbid psoriatic arthritis: an analysis of the APPRECIATE study [abstract]. European Academy of Dermatology and Venereology: Abstracts from the 28th Congress Madrid Spain October 9\u201013 2019."}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr2.11156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.11156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:21:36Z","timestamp":1759425696000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/acr2.11156"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11156","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"2019-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}